Decylprodigiosin: a new member of the prodigiosin family isolated from a seaweed-associated Streptomyces

Front Pharmacol. 2024 Mar 21:15:1347485. doi: 10.3389/fphar.2024.1347485. eCollection 2024.

Abstract

Bioprospecting actinobacterial secondary metabolism from untapped marine sources may lead to the discovery of biotechnologically-relevant compounds. While studying the diversity and bioactive potential of Actinomycetota associated with Codium tomentosum, a green seaweed collected in the northern Portuguese cost, strain CT-F61, identified as Streptomyces violaceoruber, was isolated. Its extracts displayed a strong anticancer activity on breast carcinoma T-47D and colorectal carcinoma HCT116 cells, being effective as well against a panel of human and fish pathogenic bacteria. Following a bioactivity-guided isolation pipeline, a new analogue of the red-pigmented family of the antibiotics prodigiosins, decylprodigiosin (1), was identified and chemically characterized. Despite this family of natural products being well-known for a long time, we report a new analogue and the first evidence for prodigiosins being produced by a seaweed-associated actinomycete.

Keywords: Streptomyces; actinomycete; bioactivity; decylprodigiosin; seaweed.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 952374 and Ph.D. grant from Foundation for Science and Technology (FCT) SFRH/BD/145646/2019. The authors acknowledge the Strategic Funding UIDB/04423/2020 and UIDP/04423/2020, provided by FCT and the European Regional Development Fund.